SWOG clinical trial number
SWOG-9229

Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot
Activated
02/15/1993
Closed
05/01/1994

Research committees

Lung Cancer

Publication Information Expand/Collapse

1998

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229).

CR Thomas Jr;DJ Giroux;KJ Stelzer;JB Craig;LR Laufman;SA Taylor;JW Goodwin;JJ Crowley;RB Livingtson Int J Radiat Oncol Biol Phys 40(5):1039-1047

1995

Concurrent cisplatin (CDDP), prolonged oral etoposide (E) and vincristine (VCR) plus chest and brain irradiation (RT) induction therapy for limited-stage small cell lung carcinoma (SCLC): Preliminary report of a Southwest Oncology Group study (SWOG-9229)

CR Thomas Jr;DJ Rector;KJ Stelzer;RB Livingston ASCO 14:363(#1111)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open